Juxin Medical Completes Series B Financing to Advance Clinical Trials and Commercialization of Integrated Cardio-Cerebrovascular Solutions

VCBeat learned at the first time that CONMIND MEDICAL (Shenzhen) Co., Ltd., an innovative medical device enterprise focusing on comprehensive solutions for cardiovascular and cerebrovascular diseases.("Conmind" for short)CONMIND MEDICAL recently announced the completion of a nearly RMB 100 million Series B financing round, jointly invested by Turing Capital, Zhuhai High tech Financial Investment Co., Ltd, Chengdu Chuanghe Ruixin, and Guochuang Qinzhi Angel Fund. The funds raised will support the clinical development and early commercialization of the company's key innovative cardiovascular and cerebrovascular products.

Since its establishment in 2020, Conmind has been dedicated to discovering innovative interventional treatment products in the fields of cardiology, cerebrovascular, and peripheral vascular care. The company's neurointerventional product pipeline focuses on comprehensive aneurysm treatment solutions, while its cardiac intervention products specialize in the repair of mitral and tricuspid valves.

The company's R&D team has decades of product development experience and has successfully developed several innovative interventional devices in the aforementioned disease areas, such asHaloChord^®Transcatheter Mitral Chordae Repair System, which can simultaneously implant two sets of artificial tendons in a single capture and allows for repeated precise adjustments of the artificial tendon length, making the surgery more efficient, precise, and the anchoring more secure. This device has already initiated multi-center clinical research across China, and the 3-month follow-up data from the cases treated so far show good results, preliminarily proving its safety and effectiveness.

HaloChord^®Transcatheter Mitral Chordae Repair System

Such asJ-Tube™ Flow Diverter Stent, The full silk imaging design provides superior visibility, and the small delivery system can treat distal small vessel aneurysms. The smooth design at the ends of the stent ensures smoother delivery and reduces vascular irritation. J-Tube™ flow diverter stent has completed all clinical trial enrollments, and its excellent handling performance and immediate surgical outcomes have received unanimous praise from doctors. The six-month postoperative follow-up data further confirms its safety and effectiveness.

J-Tube™ Flow Diverter Stent

Currently, the company has received NMPA approval for five neurointerventional devices., core products have entered the clinical stage and are proceeding smoothly. In 2023, the company has completed the formation of its commercialization team, and related sales and marketing efforts are underway.

This successful round of financing reflects the investment institutions' affirmation and solid confidence in Conmind's strong R&D capabilities, highly efficient progress in its product pipeline, and commercial operation abilities.

Hui Huang, Co-founder of Conmind"We have always adhered to addressing real clinical needs, upholding the innovative concept of 'offering what others don’t have, and excelling where others do,' closely following the policy direction of domestically produced alternatives replacing imported ones. In response to the various clinical shortcomings of imported products, we have independently developed a series of high-quality innovative devices that better align with domestic clinical needs and doctors' surgical habits. The flow-diverting stent, which gained significant recognition from doctors in China during clinical trials, is a highly successful example. Over the next three years, the company will also receive certifications for 3-5 key innovative products, further increasing the market share of domestically produced interventional devices in relevant fields. At the same time, we will rely on efficient operations and production to reduce patient expenses and the burden on health insurance."”

Wang Xiaoyan, Chairman of Turing Capital"We are deeply impressed by the highly efficient execution and excellent product output of the Conmind team after a long period of project tracking and communication. The team has rich experience in the commercial operation of the domestic market and has achieved tremendous success in the past. Such an outstanding team configuration is rare among current startups. With the deepening trend of aging in China, the huge market demand for cardiovascular and cerebrovascular diseases will undoubtedly continue to rise. We believe that under the leadership of such an excellent team, CONMIND MEDICAL's high-quality, China-produced devices will definitely occupy a significant market share in China."”

Investor: Zhuhai High tech Financial Investment Co., Ltd"It said: In recent years, China's medical device market has grown rapidly, becoming the second largest market globally, and will maintain a high growth rate. Relevant national ministries and commissions continue to support the development and application of domestically produced medical devices to achieve the replacement of imported products with domestic ones. We will fully support the company in growing stronger and larger, help it fill the gaps in the field, grow into a leading enterprise in the cardiovascular and cerebrovascular fields, accelerate the substitution of domestically produced medical devices, and usher in a new market landscape."”

Investor: Shenzhen Guochuang Qinzhi Angel FundRepresented: "Conmind, as a company focusing on 'treating the heart and brain together’Conmind, focusing on the two major fields of neurointervention and structural heart disease, has enormous market potential. The company boasts a rich product pipeline, covering the main segments of neurointervention such as access, hemorrhagic, and ischemic conditions, as well as key procedures in mitral valve repair. In the field of neurointervention, its flagship products include the flow diverter stent and coil-assisted stent for hemorrhagic applications; in structural heart disease, it focuses on chordae implantation and cardiac suturing systems—areas with fewer players in mitral valve repair. These are niche blue ocean sectors within popular large tracks, offering the potential for differentiated competitive advantages. Conmind's commercial strategy of combining blockbuster products with a comprehensive product line layout positions it to leverage its strengths and quickly become an industry benchmark in the integrated treatment of heart and brain diseases.”